Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2017 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced upcoming Trials in Progress poster presentations for its two lead product candidates, CX-072, a PD-L1 targeting Probody therapeutic and CX-2009, a Probody-drug conjugate targeting CD166, at the European Society for Medical Oncology Annual Meeting from September 8-12 in Madrid, Spain.
Abstract Information:
| Title: | The First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial to Assess the Antitumor Activity and Tolerability of the Probody Therapeutic CX-072 as Monotherapy and in Combination With Ipilimumab or Vemurafenib in Solid Advanced Tumors and Lymphomas |
| Author: | Valentina Boni, M.D., Ph.D., START Madrid-CIOCC, Madrid, Spain |
| Date: | Monday, September 11, 2017 |
| Time: | 1:15 p.m. – 2:15 p.m. |
| Location: | Hall 8 |
| Abstract: | 423TiP |
About the PROCLAIM-CX-072 Trial:
The PROCLAIM-CX-072 (PRObody CLinical Assessment In Man) study is designed to evaluate tolerability, and preliminary antitumor activity and translational biomarkers of multiple doses of CX-072 as monotherapy or as combination therapy with ipilimumab or vemurafenib in patients with advanced, unresectable solid tumors or lymphoma. This first-in-human, open-label, multicenter, dose-escalation, phase 1/2 study of CX-072 includes 4 dose-escalation groups (monotherapy, Part A; 2 ipilimumab combination schedules, Parts B1 and B2; vemurafenib combination, Part C), a stage testing biomarkers and efficacy in PD-L1+ tumors (Part A2), and a dose-expansion phase (Part D).
Abstract Information:
| Title: | PROCLAIM-CX-2009: A First-in-Human Trial to Evaluate CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors |
| Author: | Javier Garcia-Corbacho M.D., Hospital Clinic Barcelona, Barcelona, Spain |
| Date: | Monday, September 11, 2017 |
| Time: | 1:15 p.m. – 2:15 p.m. |
| Location: | Hall 8 |
| Abstract: | 422TiP |
About the PROCLAIM-CX-2009 Trial:
The objectives of the ongoing PROCLAIM-CX-2009 (PRObody CLinical Assessment In Man) module are to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose-limiting toxicities, and preliminary antitumor activity of CX-2009 as monotherapy in the following 7 selected tumor types with high CD166 expression: breast carcinoma, castration-resistant prostate carcinoma (CRPC), cholangiocarcinoma, endometrial carcinoma, epithelial ovarian carcinoma, head and neck squamous cell carcinoma (HNSCC), and non–small cell lung carcinoma (NSCLC).
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of Probody™ therapeutics. Probody therapeutics exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1 and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
Media Contact:
Spectrum
Christine Quern
[email protected]
202-587-2588
Investor Contact:
Trout Group
Pete Rahmer
[email protected]
646-378-2973
